Home/Pipeline/MS Repair Programs

MS Repair Programs

Multiple Sclerosis

Not SpecifiedActiveN/A

Key Facts

Indication

Multiple Sclerosis

Phase

Not Specified

Status

Active

Company

Biogen

About Biogen

Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.

View full company profile

Therapeutic Areas

Neurology Immunology Rare Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Evobrutinib	Merck KGaA	Phase 3	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
REBIF (interferon beta-1a)	EMD Serono	Approved	Active (Lifecycle Management)